AngioDynamics (NSDQ:ANGO) won FDA clearance for its BioFlo peripherally-inserted central catheters, the company announced this week.
BioFlo is AngioDynamics’ 1st device to include the proprietary Endexo technology for reducing the accumulation of blood clots on and in the catheter, according to a press release.